This speculative drug stock is targeting the growing global problem of hospital-based infections.
The stock has had a great run, meeting aggressive targets.
These defensive plays yield up to 8%. And best of all, it's not too late to buy.
Some major branded drugs will lose patent protection, and market share along with it, this year.
The pharmaceutical company's new CEO formerly worked for the Canadian company, long a rumored suitor.
The biotech was rumored to be a takeover target but aims to be a buyer instead.
Ford is downgraded to 'hold,' and Novartis is upgraded to 'buy.'
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.